Skip to main content

Partnering strategy

ReproNovo’s strategy is to forge impactful partnerships in both in-licensing and out-licensing collaborations. For advanced clinical programs, we seek strategic alliances to maximize the commercial potential of our current assets while actively pursuing in-licensing opportunities for earlier clinical stage candidates (Phase 1 or later) in reproductive medicine and women’s health. Our expanding portfolio comprises first-in-disease compounds that are tailored to address underserved areas in those fields.

Commercial opportunities

With a proven track record in design and execution of clinical development programs, our experienced team is poised to drive innovation and deliver impactful solutions to improve outcomes of fertility treatments and aid with women’s health conditions. The potential of our assets capitalizes on commercial opportunities within the growing fertility and women’s health markets.

RPN-001 (leflutrozole) a novel approach to male infertility

Infertility is a growing healthcare challenge around the world due to lifestyle, environmental and genetic factors. Approximately one in six people have experienced it at some point of their life. At the same time, more and more people have access to modern treatments options to fulfill their family dream. The causes why a couple cannot conceive are complex and a thorough diagnosis needs to be established. Male infertility associated with low serum testosterone is becoming more prevalent. In recent years, the prevalence of low testosterone in men under 40 years has increased five-fold to 20-23%.

Whether the cause of a couple’s infertility lies with the male or the female partner, often they turn towards assisted reproductive treatments (ART), which in many cases mean in vitro fertilization (IVF). Alternative treatment options targeted directly to men could provide solutions to a significant number of couples seeking fertility. For infertile men with low serum testosterone, leflutrozole has the potential to become this alternative treatment option.

 

RPN-002 (nolasiban) a new molecular entity for embryo implantation and adenomyosis treatment

Enhancing success rates of assisted reproductive technologies

The process of implantation after embryo transfer in an assisted reproductive technology cycle is pivotal for the probability of treatment success. Establishing uterine quiescence and enhancing endometrial blood flow during the process of implantation are expected to increase pregnancy and live birth rates. While many other aspects of assisted reproductive technologies have been addressed over time, drugs targeted at enhancing embryo implantation are not yet available.

A first-in-disease compound to manage adenomyosis

Adenomyosis is a common uterine disorder, associated with painful symptoms such as severe menstrual cramps, heavy and prolonged periods and pain during intercourse. This condition is also accompanied by difficulties in conceiving. Abnormal uterine contractility is thought to be involved in the pathogenesis and progression of adenomyosis. Research has shown a link between oxytocin receptors and symptoms of adenomyosis. This suggests that RPN-002, as an oxytocin receptor antagonist, could have a positive impact on women with this condition. Currently, there are no approved drugs specifically for adenomyosis.

”

  • It’s difficult to watch my wife shoulder the burden of IVF treatment, the constant hormone shots and clinic visits. There is a constant battle between feeling full of guilt, helplessness and wanting to do more to support her through this journey. It’s not just about her physical discomfort or the financial strain; it’s about the emotional toll of watching the person I love endure so much for our dream of starting a family. Having a drug that I could take to improve my sperm count, would be a game-changer from my perspective.

    – Matt, male patient with secondary hypogonadism –

  • I have been through the emotional rollercoaster of IVF to turn my dream of having a baby into reality. Today, I am a proud mother of a two-year-old son. However, several treatment cycles failed, which was a crushing experience. The possibility of enhancing the chances of successful embryo implantation would fill many women with renewed hope.

    – Nicole, an IVF patient –

  • As someone living with the daily pain and challenges of adenomyosis, the need for treatment options is urgent and deeply personal. We deserve options that offer real relief and a chance to live without constant discomfort or having to make the agonizing decision to undergo a hysterectomy.

    – Sarah, who is suffering from adenomyosis –